SELLAS Life Sciences Virtual R&D Day: Advancing Galinpepimut-S (GPS) and SLS009 in AML

SELLAS Life Sciences Virtual R&D Day: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update [Streamed on 29 Oct. 2025]